Media Kit 2012 Special Discount Rates for Early Space
Transcription
Media Kit 2012 Special Discount Rates for Early Space
Media Kit 2012 Drugs Devices Injectables Skin Care Sunscreens The annual side-by-side comparison of every product in dermatology Editor-in-Chief: Perry Robins, MD Co-Editors: Kenneth R. Beer, MD Joseph B. Bikowski, MD Joel L. Cohen, MD Mitchel P. Goldman, MD Mary P. Lupo, MD Maritza Perez, MD Neil S. Sadick, MD Special Discount Rat es for Early Spa ce Reservation Media Kit 2012 FROM THE EDITORS OF JDD Apr il 2011 ISSN: 1545 • Volume 10 • Issue 4 9616 EDITOR-IN-CHIEF: Perry Robins, MD Professor Emeritus of Dermatology NYU Medical Center, NY CO-EDITORS: J DD OPIC: SPECIAL T LIGHT LASERS AND SOURCES the rfacing for Laser Resu page 340 ISSN:Image 1545credit 9616 of Fractional Ablative CO2 Striae ew Scars and y and Revi , Photoaging, Clinical Stud of Rhytides of y Treatment tmentMa for the Trea y erap toth B Light Pho Ultraviolet iasis Narrowband to Severe Psor limumab Plus Moderate Multi-Center Kenneth R. Beer, MD Voluntary Assistant Professor University of Miami, FL Joseph B. Bikowski, MD Clinical Professor of Dermatology Ohio State University, OH 2011 • Vol ume 10 • Issue 5 Ada Cream Fluorouracil With Topical ial Therapy tosis of Sequent of Actinic Kera Assessment Treatment Case-Based -PDT for the : Prospective, 0.5% and ALA vulinic Acid nole Ami Therapy With todynamic tiva by Pho itis Suppura Results of Hidraden Preliminary Treatment Laser ye ed-D nm Puls a Novel 607 hromia With of tment of Dysc and Safety Laser Trea e the Efficacy to Evaluate nts Who Hav Pilot Study iasis in Patie ive Cohort Plaque Psor bel, Prospect e to Severe n-La erat limumab Ope Mod An nt of onse to Ada in the Treatme quate Resp pt Ade erce an Etan Not Had poreal a and Extracor Alph n fero Syndrome tion With Inter and Sézary at in Combina Fungoides of Vorinost e Mycosis The Efficacy is in Late Stag ling? Photopheres Class Labe ciation or a : A True Asso retin Acit and Guest Edited VIEWS Depression ELINE PRE J DD SPECIAL T O PIC: SKIN OF CO LOR RESIDENT ROUNDS TRIAL Image credit page CLINICAL Advances by AndrewPIP REVIEW F. Alex is, MD MPH 456 in the Trea tment of Kelo ids Topical Reti noids for Pigm Fillers in the Joel L. Cohen, MD Clinical Assistant Professor of Dermatology University of Colorado, CO Progressive Topical Tacr olimus is Mor e Effective ented Skin Skin of Colo r Population Macular Hyp omelanosis for Treatme nt of Vitiligo Scalp Hyperke ratosis and A Survey of Melasma in Alopecia in in Patients Children of of Skin of Colo r Color Latin Ame ricans Skin Conditio ns and Con cerns in Sou th Asian Ame ricans: A Com An Over-the munity-Based -Counter Moi Study Prescription sturizer Is Barrier Crea as Clinicall ms in the Trea y Effective as, and Mor tment of Chil e Cost-Effe dren With ctive Than Randomized Mild-to-Moder , , Controlled ate Atopic Trial Dermatitis :A Infliximab Treatment for Psoriasis in 120 Patie nts on Ther apy for a Min RESIDENT imum of One ROUNDS Year: A Revi CLINICAL ew TR Mitchel P. Goldman, MD Clinical Professor of Dermatology/Medicine University of California, CA IAL REVIEW PIPELINE PREVIEWS Mary P. Lupo, MD Clinical Professor of Dermatology Tulane Medical School, LA Maritza Perez, MD Director of Cosmetic Dermatology, St. Luke’s Roosevelt Medical Center, NY EXCELLENCE THROUGH PEER-REVIEW Neil S. Sadick, MD Clinical Professor of Dermatology Weill Medical College of Cornell University, NY Faculty for The Derm Directory 2012 is subject to change. CONTRIBUTING AUTHORS Hillary Baldwin, MD Kenneth Beer, MD Brian Berman, MD, PhD Brian Biesman, MD Joseph Bikowski, MD Barry Blass, MD Michael Bukhalo, MD Mitchel Chasin, MD Joel L. Cohen, MD Steven R. Cohen, MD Karen Davis, MD Nina Desai, MD Cherie Ditre, MD 2 Lawrence F. Eichenfield, MD Alan B. Fleischer, Jr., MD Joseph Fowler, MD Dore Gilbert, MD Richard G. Glogau, MD Michael Gold, MD Linda Stein Gold, MD Gary Goldenberg, MD Mitchel P. Goldman, MD Roy C. Grekin, MD Pearl E. Grimes, MD Jeffrey Henning, MD Bruce Katz, MD Steven Kempers, MD Evan Leibowitz, MD Christine Liang, MD Rebecca Lu, MD Mary P. Lupo, MD Gilly Munavalli, MD Vic Narurkar, MD Chris Nelson, MD Perry Robins, MD Theodore Rosen, MD Neil Sadick, MD Ritu Saini, MD Deborah Sarnoff, MD Joel Schlessinger, MD, FAAD, FAACS Sejal Shah, MD Stacy R. Smith, MD James Spencer, MD Monika Srivastava, MD Hema Sundaram, MD Wil Tutrone, MD Jennifer Williams, MD Debbie Zell, MD William T. Zempsky, MD The Derm Directory 2012 Media Kit 2012 OVERVIEW : WHAT’S IN IT FOR YOU The Derm Directory is a point-of-care reference that builds brand awareness, generates leads, and establishes your company as a key supporter of a highly-requested educational resource. Reach the entire dermatology community during crucial decision-making moments with premium listings, advertising, and sponsorship options. Premium Listings: Highlight your brand with a full-page product spotlight in the most comprehensive dermatology reference guide Custom Sponsorships: Provide an invaluable resource to practitioners through customized conference distribution, direct mailing to key prescribers, hand-delivery by your sales representative, and branded smartphone/tablet apps Multi-media Platforms: Effectively deliver your message in print, online, and via smartphone A CREDIBLE RESOURCE FOR DERMATOLOGISTS The Derm Directory serves as a complete compendium of therapeutic and cosmetic modalities with information on drugs, devices, injectables, skin care, and sunscreens. Like the Physicians’ Desk Reference (PDR®), The Derm Directory is kept and referred to throughout the year and it plays a direct role in product selection at the time of treatment. It includes every dermatology product available in the United States within the following 5 categories: Drugs (Rx only) Devices Injectables Skin Care Sunscreens 98% of doctors surveyed said The Derm Directory would influence their prescribing habits AUDIENCE AND REACH The Derm Directory reaches ≈14,500 dermatology healthcare professionals including: Dermatologists Residents & Fellows Physician Assistants Nurse Practitioners New for 2011 Drug Peri-procedure Considerations Chart Revised Device Categories Coming in 2012 Facial Moisturizers with SPF Section DISTRIBUTION Available: Print Launch: March 2012, AAD’s 70th Annual Meeting Mobile: March 2012, AAD’s 70th Annual Meeting (pending sponsorship) Print Fulfillment: March - May 2012 Sponsorship opportunities to practitioners outside of the field of dermatology are available; contact an Account Executive for more information. The Derm Directory 2012 3 Media Kit 2012 THE DERM DIRECTORY: FEATURES & CONTENT NeoStra ta Comp skin active hbeam s s Xv hshape rus Hr solera Opus solera titan injec sola o Xl sopran 500 care tar r tattoos tar Y tattoos tM ge cPt therma scan therma rm transde trios el ultrape e ultra Puls reens ies varia varilite ns vectra M3 pe ii velasha s5 velure s9 velure contact mfr. erm vibrad suns viridis 60 79, 87 57, 67, includes a wide rang products e of ther 72 apeutic to including treat a variety of cond aged skin 89 ition s acne, psor , hyperpig men iasis, pho to damage, 80tation, chronic dry skin and . Products comedo are non64 genic and some are for sens itive skin formulate 77, 85 . Total # 56,d of products :4 80, 55, 75, includes a wide rang 82, 88 products e of ther apeutic to including treat a variety of condition 68 aged skin s acne, psor , hyperpig mentatio iasis, pho n, 62 to damage, chronic dry skin and . Products comedo 85 are non77, genic and some are for sens itive skin formulate . Total # 70 of products d :5 89 2011 Skin Co-Cha irmen $76.00 Andrew MPH, FAF. Alexis, MD, AD $199.00 faCulT y indd 114 1/14/11 2:19 PM ory 201 rm Direct The De ices gs_Dev 2011 Dru .indd bles _Injecta CEO Cultur Laser Washin Go to Skin Cheryl ofColorSem M. inars.c Zoe Dia Burgess, MD, na FAAD Amy Mc Draelos, MD M Michael , MD Su Jes Director y 2011 nscreen. 1 52 Elio Director Skin of Colo r Center St. Luke’sRoosevelt and Beth New York Israel , NY 78 _Care_Su derma contact mfr. 73 114 The Derm venus-i cree $26.00$60.00 74, 91 sunsc vbeam SkinofC 1/14/11 52 To reg olorSemi 1:00 PM S12042 Filler Ad.in dd 1 Online Version: TheDermDirectory.com JDDonline cross-promotion increases online traffic Automatic online listing Advanced search capabilities Reference articles directly linked to PubMed® abstracts Worldwide complimentary access among all healthcare professionals “MyList” functionality: stores selected products of interest by category for quick reference and side by side comparison 4 lo TreaTin $15.50$38.00 brandMd acne defe system nse brandMd age defe nse system e triactiv uv ser Skin of Co MSrp 88 technolo gy drive 74, 91 n, med clinically tested. Form ical grade, 62 extracts 58, ulate d with herb and phys iologicall al nutrient y active s. Total 57, 86 # of prod ucts: 51 72 o HP synchr ie synerg light ie elite synerg er ta2 eras ct tar effe tattoos care skin Neutrad erm, inc. neutrad erm 877-252- .com 7546 brandMd skin inje c ta b les sP Plus starlux CT liNE Antiacne drug es t HP ide dO ta b l e ces kin cO 2 hcool prOdu 60 neostra ta® slimlipo X ipo MP smartl lex ipo triP smartl smoot ry wiTHiN 60 skintyte smoot Formulate d and utiliz for therapeutic use es polyhydr key ingredients such as oxy acid (PHa lactobion ic acid, and ) gluconolacto ne, care for glycolic specific acid to skin cond offe ition 88red. Total # 84, of products s. kits are 55, 76, : 10 adjunctiv e ther apeutic 55, 82 that imp products rove the visible sign aging and 84 s of 65, can trea t acne, dry hyperker atos skin, 61 more with is, skin discolor ation, and advanced tech hydroxy 85 nology inclu acid ding alph acids (aHa a-hydrox s), polyhydr y 64, 83 and oxy acid polyhydr s (PHas) oxy bion also inclu ic acids. 83 des Psor line ent® for Total # of psoriasis products . 63 : 34 Potent antia 70, 65, formulate 56, 61, ging of-the-ar 88 84, d with state ingredie 72, t76, nts such neogluc as: patented osamine™ 78, , apple stem extract,57, 62, 70, Peptides cell , chardon seed extr86, 89 nay grap act, glyc e olic Polyhydr 76, 84 acid, retinol, oxy/ 64, bion and ic acids. appeara reduces nce of deep the by build 60 lines and ing derm wrin kles al collagen Please see and gag full73page s. details. Total # of listing for more products 77, 92 :4 91 59, 74, 62 sinon smoot CATEgO KEy fEA TurES Antioxid ant Chem ical Peel Clea nser Em ollie nt Exfo liato r Eye Trea tmen Fine t Line Repa Gro ir wth Fact or Pigm ent Redu Pre/ cer post Proc edur Retin e ol Scar ring Suns cree n ta Compan y neostrata 72 .com 78, 92 800-225941167, , inc. 86 ticals® 62, l smartX Wrinkle Reduction Leg Veins COMpAN y/ prOdu CT liNE # NeoStra page neoceu silkPee smarts raderm age Tattoo Removal Skin Resurfacing Skin Rejuvination Psoriasis & Vitiligo Pigmentation & Vascular Lesions Hair Reduction Body Contouring, Cellulite & Tightening Acne Non-Laser Light Microdermabrasion Intensed Pulse Light (IPL) Imagine System e CO2 – 10,600 nm DeviC Nd:YAG – 1320 nm Nd:YAG –1064 nm Diode – 800 nm Pulse Dye Laser – 595 nm Ruby Laser – 694 nm Alexandrite – 755 nm Type of Er:YAG – 2940 nm t devic T KTP – 532 nm Excimer Laser – 308 nm s drug UC proD devi Section comparison tables for comparative product assessment Company contact information on Char mparis Co Device Radiofrequency (RF) & Us Tions inDiCa 5 product categories: Rx Drugs, Devices, Injectables, Skin Care, and Sunscreens Descriptive visual legends for general information on each product any - Ne ut s Print Version The Derm Directory 2012 iSTer nars.co m Media Kit 2012 THE DERM DIRECTORY: CONTENT & FEATURES xample of E General Listing ® atralin ical (tretinoin) 45 g the ted for 05% gel, is indica s of age 10 year ralin Gel age: at patients uS in D is an ar vulg ® (clindamycin ionS ne at ac iC D of in t 2% phate 1. mmon treatmen most co ycin phos topical nS: the : clindam r. dry skin, DiCatio r the PPLieD include and olde ntrain this can cated fo or HoW Su di n. Co e side in D tio es is g th ita an l, 50 CtS a Gel me of skin irr years fe so is ny l 12 ef g. ca s 2.5% ge e ge in A D nt el atralin e: lin Si in patie D uSag with atra ssive flaking or pe r you have used vulgaris e effect me a te ionS an ce af co sid ne at ex ss be ac iC s, le s D u ct es of in e effe ther yo g, redn nical while, tment sid in bo cli e ea rn d tr or es l l bu lle th ay ro ge for a topica doctor if ay go aw g atralin S: in cont curred in effects m . tell your stop usin iCation you use oc ks D to ee ve ns n u older. w ha ai tio yo w ntr ask tions e reac r a fe ing, or n-site ay rs Co fo ac us l m tio D ve re e ge e or ica ar ad an rs ct pl u e l: ap adve feCtS . Your do of atralin gel yo ication-sit tionacanya ge SiDe ef t common rred within the problem ing appl the mos cu amount ated with .1%), and applica ous e follow not ce a day. (0 tients tre in, and oc ne ange the trials, th ld n on ta sk pa ch ou e tio cu an of sh th lia th l ed 0.2% l less e exfo tion of ralin ge re perienc ng, less than atralin ge moderate irrita ication-sit or stingi s who ex lin gel. at potential for seve %), appl to ing, and/ e patient with atra pain (0.1 as wind cases ng, burn were mild ks of treatment in due to %). Of th ch hi .1 of sk su (0 d itc , ity n es g, ne or tio extrem sunbur t, and w wee a, scalin the maj fe er d m or en y, site irrita s th st te m he ap fir ou ea at ec yt er at prot ith w s of er rly in tre ith a hip to th on eczem avoid un lin gel w symptom tients w curred ea relations be used e of atra ial for irritation. verity, oc raindicated in pa ssociated ss of the avoid us creased to potent ate in se regardle -a nt and ial for in irritation. gel due to moder gel is co antibiotic rted with t sPF 15 to potent g atralin as e in le du us at were mild ereafter. acanya rative colitis, or n po ld if whe en re or co een of ht cr be th ce caution ig ns d ul ve nl su if se ith is, su ha e d w gel re to n. us decrea ende nts enterit colitis lin su m tio d al ra m po iza an on at , co ex sit gi n. e re ea in re ei Patie en us uation is dy diarrh fish prot posure. applying d photos history of care increase enicity to rhea, bloo amycin. discontin advised to avoid during ex th g ar rg ng al in le di wi al th he is. r llo r colit t thei s are tive clo sure fo l clind ntial fo nt ac ec po te ca nt tie ot pi ex po co n pr Pa to . to ld su ou fish due the use of arrhea develops and to minimize ticaria sh allergic to t di lips, itus or ur euticals significan , or nose, or on lop prur als Pharmac es who deve maceutic valeant mouth, ey n of acanya gel. ant Phar le . va er vision of id of di tio prov ries, a division to a ra s, the applica bo rie to a la a labora ny: cOri om ny: cOri ComPa ralingel.c l.com ComPa erica .com at acanyage erica north am corialabs labs.com north am 37 ria 19 co 61937 800-55 800-556xide oyl pero and benz de) nzoyl peroxi phosphate-be acanya H oW eD: 0. SuPPLi Information on All FDA-approved Rx Drugs, Devices, and Injectables in Dermatology and All Physician-dispensed Skin Care and Sunscreen Product Lines s evice drug s p acne: to d aczone bles ® d 60 g l, 30 g an e ted for th is indica ge LieD: 5% are skin c reens PPLieD Benzac HoW Su • Lists: How Supplied, Indications and Usage, Shelf Life, Duration, Side Effects and Contraindications, and Company Contact Information • Organized by therapeutic categories such as “Dermal Fillers” INJECTABLES sunsc DEVICES ) Premium product listing with expanded information atment of for the tre dicated elex is in is. age: az ar uS lg D vu ionS an ory acne cts may inDiCat erate inflammat g, side effe od sh, peelin ationS: mild to m ainDiC hema, ra ng D Contr ng, tingling, eryt actions, worseni an S feCt rgic re g, stingi le in s, al rn ot SiDe ef s, sp iti bu ted rmat en uritus, de t pr gm ac pi de es nt all de inclu herp s, co dermatiti recurrent tation, sm irritation, depigmen exacerbations of a, vitiligo g, and of asthm reddenin is, os ich hypertr labialis. rgan, inc. ny: alle m ComPa lergan.co 4500 al 714-246- HoW Su g ment, 25 for the : 2% oint dicated ycin is in e: akne-m ag uS anD S n ay io effects m inDiCat vulgaris. nS: side s, t of acne DiCatio oily skin, pruritu treatmen ntrain a, m Co he D yt an s, er zer. feCtS g, drynes d sensiti SiDe ef g, peelin atitis, an in euticals rm rn ac de m bu t include ant Phar e, contac n of vale l resistanc a divisio bacteria ratories, bo la a ny: cOri ComPa erica m north am rialabs.co 1937 co 655 080 • Lists: Company Contact Information, Type of Device, Indications and Usage, Wavelength, Energy Output, Pulse Duration, Cooling, and MSRP • Organized by therapeutic categories such as “Rejuvenation (Nonablative)” or “Hair Reduction” • Comparison chart: Type of Device and Indications & Usage ® (azelaic acid) azelex : 20% cream, 30 g and 50 g (erythromycin PPLieD (tretinoin) LieD oW SuPP L ® ycin akne-m HoW Su oz ® oxide) aC (benzoyl per gel, 60 g; 5% and 10% wash, 8 atment PPLieD e tre 10% ted for th : 5% and is indica nzac ac age: be D uS ionS an inDiCat aris. lg of acne vu 1/14/11 1:19 PM 2011 .indd 12 jectables vices_In ugs_De Generic equivalent SKIN CARE ory rm Direct New product, FDA-approved 12 The De since 2009 2011 Dr • Lists: Company Contact Information, Product Line, Key Features, Category Within Product Line, and MSRP • Organized alphabetically by company name Use in lactating women is “safe” or “probably safe” FDA-approved for pediatric use (≤11 years) FDA-assigned pregnancy category The Derm Directory 2012 SUNSCREENS L g g and 45 cream, 20 atment of gel and : 0.025% for the tre d te ca di H avita is in uSage: D an de skin S ion cts inclu inDiCat is. side effe ar ationS: king or peeling. acne vulg ainDiC fla tr n ive ss Co D exce feCtS an rning, redness, SiDe ef bu dry skin, als, inc. irritation, maceutic ar Ph n ny: Myla ComPa ylan.com 9526 m 800-796- avita ® t of treatmen PP e: aczone D uSag ionS an d nings an inDiCat is. s nS: War ar DiCatio one treatment ha and acne vulg ntrain ps Co da signs D if al . Or ia an effects: feCtS ic anem l yt ef ica ol e l m D og Si ge 5% atol d he r, aczone ns: Hem nts olysis an ted hem Precautio emia occu t be used in patie dose-rela of hemolytic an no ld ou cause of sh e produced ggestiv gel 5% tions be su ne ica s zo 5% ed l om m ac ued. sympt alarial zone ge discontin e or antim mbination of ac the should be ng oral dapson increase ns. co taki ic reactio ost sMX) may who are y. the m r hemolyt hoxazole (tMP/ nc fo l ie ia fic nt ) are Pd de famet 0% ul g6 the pote /s ≥1 ith im w ce ciden ethopr tients m (in pa tri in 5% l is ith e. w ge olys n sit d of hem of aczone at the applicatio likelihoo reactions ma adverse d erythe common yness, an eling, dr pe s/ es oilin ne.com rgan, inc. ny: alle m aczo ComPa lergan.co 4500 al 714-246- HoW Su ta injec (dapsone) DRUGS • Lists: How Supplied, Indications and Usage, Side Effects and Contraindications, and Company Contact Information • Organized by therapeutic categories such as “Acne: Topical” • Comparison chart: Active Ingredient, Company, Pediatric Age, and Pregnancy Category • Lists: Company Contact Information, Product Line, Key Features, SPF: Active Ingredients, Category Within Product Line, and MSRP • Organized alphabetically by company name 5 Media Kit 2012 PREMIUM LISTING: EXAMPLE Premium Listings Stand out from your competitors with a visually-enhanced and clinicallyrelevant full-page product listing dedicated exclusively to your product! Clinical References In-depth Product Descriptions Clinical Pearls and Key Features from a KOL Influential Physician Commentaries Secure Your Premium Listing Toda y Ways To Maximize Your Premium Listing: Product recognition pical eratosis: To and awareness r & Actinic K Skin Cance ® d) Cre Zyclara (imiquimo drugs am, 3.75% clinical Pe devices bles nt the treatme and 3.75% for face ArTiCleS: uimod 2.5% lication to the b, et al. imiq ies of daily app W, berman trolled stud 82-590. n, abramovits . 2010;62(4):5 2 placebo -con of atol 1. swanson lts Derm resu d toses: actinic es. J Am Aca of actinic kera clearance of 2-week cycl th sustained scalp for two lied and balding al. twelve mon and 3.75% app of berman b, et uimod 2.5% n academy n, Hanke cW, p after imiq 68th america 2. swanson or balding scal presented at: ter the full face of Pos s es. tosi cycl kera mi, Fl. eek or 3-week Mia 2-w zed, ; omi two 2010 for ch a rand ; Mar daily g t, lev y s. ual Meeting Men j, % ann y 3.75 kulp of olog dermat bourcier M, safety study lebwohl M, , efficacy and s. J Drugs Markowitz O, multicenter nic keratose 3. jorizzo j, -controlled, tment of acti ded, placebo ery for the trea double-blin wing cryosurg cream follo imiquimod 08. 1-11 ;9(9):110 Dermatol. 2010 skin care ens ry: rapy for n for field the ients ellent optio lly use it in pat am is an exc (ak). i typica “Zyclara cre in my inic keratosis cryosurgery act ing h low wit ts fol ll patien dies and works we stu it l ica and ’s clin ak in le efficacy erm with multip , two g-t off lon excellent on, two weeks practice. it has of two weeks atment course a simple tre erg, MD week on.” Gary Goldenb ogy y and Pathol log ato rm fessor, De Assistant Pro of Medicine ool Sch ai Mount Sin New York, NY referenCe CompAny: s, llc armaceutical graceway Ph 800-328-0255 m aypharma.co www.gracew cream.com www.zyclara petent adults. ion or immunocom edema, eros ing scalp in ing or dryness, full face or bald rruptions flaking, scal s (ak) of the dosing inte or crusting, s can occur. hema, scabbing emic signs and symptom eryt ded inclu ike syst tions nt of clini . these reac s and/or flu-l tme area tion trea ion reac cal y licat ator s in the app d for the topi local inflamm m is indicate skin reaction erate. intense Zyclara crea effects involved as mild to mod t common side s were rated cream. ies, the mos t skin reaction use of Zyclara in clinical stud exudate. Mos imized during weeping or avoided or min be ld ulceration, and shou nt) ired. uva/b treatme or s bed may be requ t (tanning icial sunligh cent page. natural or artif tion on adja exposure to ing informa Full Prescrib f summary of Please see brie visible or cally typical nic keratose 1 Directory 201 44 The Derm ©2010 Graceway Pharmace uticals, LLC, Bristol, TN www.gracewaypharma.com www.ZyclaraCream.com ZYC031093 TheDermDirectory.com 6 Change th of AK treat palpable acti sunscreens sunscre drugs cOMMenta Prescribing information summary printed adjacent to listing for easy reference i n j e c ta b l e s i n j e c ta Skin Cancer & Actinic Kera tosis: Topical devices Age: of clinically nS And uS l treatment indiCATio for the topica full face or is indicated ses (ak) of the Zyclara cream palpable actinic kerato or adults. t ten pe typical, visible in immunocom balding scalp nS: rAindiCATio ma, edema, S And ConT ctions, erythe Side effeCT usting and local skin rea , scabbing/cr may include ess s ect ryn eff g/d e sid e headache, ing/scalin lud flak , inc ate ns ud ed reactio ort weeping/ex on adjacent rep n er atio Oth ration. ibing inform erosion/ulce er. see Prescr sea, and fev fatigue, nau page. re skin ca y Features: rse a simple cou ly dosing in » Once-dai / 2 weeks on / 2 weeks off on eks we • 2 1 can’t the ones you can see—and lesions you ted lesions » treats the usly undetec vio pre had ients • 86% of pat treated revealed and ained clear lara cream rem ared with Zyc wh ients o cle nt1 cou ion » Many pat les ion in overall • 82% reduct nce1 plete cleara ients had com 1 • 36% of pat the tial clearance par had reduction in • 59% ed as >75% arance defin – Partial cle s at baseline ion les of er lesion numb nce remained plete cleara 2 ients with com nt me • 40% of pat eat nths posttr free at 12 mo of cream lied: tain 250 mg How Supp kets which con single use pac a box of 28 Optional before and after photos and clinical data tables/graphs arls and ke Please see important safety inform ation 45 The Derm Directory 2012 on Media Kit 2012 PREMIUM LISTING: COST-EFFECTIVE MARKETING Added Value Red starburst distinguishes your product among the general listings and in the comparison table Inclusion in the print and online Buyer’s Resource Guides for year-round lead generation On TheDermDirectory.com, premium listings are highlighted and listed before general listings Conference distribution and promotion at Orlando Dermatology Aesthetic & Clinical (ODAC) conference, ASDS Annual Meeting, and the AAD Meetings Direct link to your website from TheDermDirectory.com Additional Product Advertising Corporate or Product Advertisement Cover Shot Cover-tip or Belly-band Custom Insert (CD-ROM, BRC, Newsletter) Online Banner Advertisements 10 complimentary copies of The Derm Directory Sponsorship Opportunities Exclusive Smartphone/Tablet App: Reach a hot, new market of mobile users—expected to rise to 81% of physicians by 2012 Conference Distribution: Hit the market first with the launch of the 2012 Edition of The Derm Directory at the AAD Annual Meeting Sales Representative Direct Delivery: Give your sales reps a great reason to call on HCPs with a premium drug reference tool Online Premium Listing Online Video Pearls Direct Mailing Fulfillment: Gain premium exposure by supporting the mailing of The Derm Directory 2012 to ≈14,500 dermatology healthcare professionals HOW IS THE DERM DIRECTORY DIFFERENT FROM OTHER ADVERTISING? Shelf Life: Generates leads for 12 months Unique Content: Comprehensive product information that is in demand Targeted Circulation: Reaches a dermatology community of ≈14,500 practitioners Motivated Readership: Year-round promotion yields strong anticipation among healthcare professionals Online Directory: Free, unrestricted online and mobile availability ensures easy, everyday accessibility Extended Visibility: Reach plastic surgeons and other aesthetic specialists with online platforms The Derm Directory 2012 7 Media Kit 2012 DON’T BE LEFT OUT IN 2012 Pricing and material specifications can be found on the enclosed 2012 Rate Card. FULL PAGE PREMIUM LISTINGS IN THE DERM DIRECTORY Reserve Your Premiu m Listing Placement Today! Acanya® Efudex® Neutrogena Clinical™ Aczone® Elastiderm® Neutrogena® Rapid Wrinkle Repair Affirm™ Elastiderm™ Décolletage System Neutrogena® Spectrum Plus Sunblock Solar Protection Formula® Affirm CO2™ Elite MPX™ Obagi® Condition & Enhance Solaraze® Gel Aldara® EndyMed PRO™ with 3Deep™ Obagi-C® Rx Solodyn® Altabax® Epiduo® Obagi Nu-Derm® SoluCLENZ Rx Gel™ ArteFill® Epiquin® Micro Olay® Pro-X Intensive Firming Kit Soriatane® Atralin® Ertaczo® Olay® Pro-X Intensive Wrinkle Protocol Sotradecol® Aveeno® Eczema Therapy Extina® Olay® Regenerist Starlux® 500 Aveeno® Natural Protection Mineralblock Fraxel re:fine® Olux-E® Tazorac® Aveeno® Skin Relief Fraxel re:pair® Oracea® Tersi Foam BenzaClin® Fraxel re:store® Dual Laser Oxistat® Thermage CPT™ Botox® Cosmetic Gemini® Pearl™ Fractional Thermage® NXT System Cleanse and Treat® GentleMax® PoxiDerm™ Topicort® CLENZIderm M.D.™ Isolaz™ Deep Pore Lazer Therapy PRN® Tretin-X™ Clobex® Spray LidoSite® Protopic® Vaniqa® CoolLipo™ LipoLite™ Renova® VelaShape™ Cutivate® Locoid Lipocream® Retin-A Micro® Velashape™ II Cutera Xeo™ Locoid® Lotion Rosaclear™ Verdeso® Foam DermaSweep MD™ Minocin® Sapphire Abrasion Veregen™ Dermatix™ Ultra Naftin® Skin™ by Nulastin Vusion® Dermatologic Cosmetic Labs® NeoBenz® Micro SD Smartlipo™ MPX Xeo™ Desonate® NeoBenz® Micro Wash Smartlipo Triplex™ Xolegel® DUAC® Topical Gel Care System Neocutis® Skin Care Lines SmartSkin CO2™ Zyclara® eSeries™ NeoStrata Skin Active SmartXide Dot™ All FDA-approved/cleared products are automatically listed; however, please expect to hear from us as we reach out to ensure all of your products are listed accurately. Please be sure to update your general listing information by November 18, 2011. DEADLINES Early Space Reservation Special 7/21/2011 (5% discount on all Premium Listings) 8 Space Reservation 10/21/2011 Premium Listing Materials Due 10/31/2011 Launch Date 3/16/2012 TO SECURE PLACEMENT OR FOR MORE INFORMATION ABOUT SPONSORSHIP OPPORTUNITIES, CONTACT: LUZ FIGUEROA Account Executive [email protected] (646) 736 4338 — office (949) 760 0522 — fax The Derm Directory 2012